Embryonic Fibroblasts Promote Antitumor Cytotoxic Effects of CD8(+) T Cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Qin, Yingyu | - |
dc.contributor.author | Shin, Jung Hoon | - |
dc.contributor.author | Yoon, Jeong-Ho | - |
dc.contributor.author | Park, Se-Ho | - |
dc.date.accessioned | 2021-09-02T12:42:25Z | - |
dc.date.available | 2021-09-02T12:42:25Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-04-13 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/76144 | - |
dc.description.abstract | Adoptive CD8(+) T cell therapy has emerged as an important modality for the treatment of cancers. However, the significant drawback of transfused T cells is their poor survival and functionality in response to tumors. To overcome this limitation, an important consideration is exploring a culture condition to generate superior antitumor cytotoxic T lymphocytes (CTLs) for adoptive therapy. Here, we provide a novel approach to generate potent CTL clones in mouse embryonic fibroblast-conditioned medium (MEF-CM). We found CTLs derived with MEF-CM have higher potential in long-term persistence in tumor bearing and non-tumor-bearing mice. Importantly, adoptive transfer of MEF-CM-cultured CTLs dramatically regressed tumor growth and prolonged mice survival. Characterization of MEF-CM-cultured CTLs (effector molecules, phenotypes, and transcription factors) suggests that MEF-CM enhances the effector functions of CD8(+) T cells in part by the upregulation of the T-box transcription factor eomesodermin. Consequently, MEF-CM enhances the intrinsic qualities of effector CD8(+) T cells to augment antitumor immunity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.subject | ADOPTIVE IMMUNOTHERAPY | - |
dc.subject | CANCER-IMMUNOTHERAPY | - |
dc.subject | STEM-CELLS | - |
dc.subject | MEMORY | - |
dc.subject | DIFFERENTIATION | - |
dc.subject | THERAPY | - |
dc.subject | EOMESODERMIN | - |
dc.subject | BET | - |
dc.subject | ACTIVATION | - |
dc.subject | TUMORS | - |
dc.title | Embryonic Fibroblasts Promote Antitumor Cytotoxic Effects of CD8(+) T Cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Se-Ho | - |
dc.identifier.doi | 10.3389/fimmu.2018.00685 | - |
dc.identifier.scopusid | 2-s2.0-85045332358 | - |
dc.identifier.wosid | 000429965900001 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN IMMUNOLOGY, v.9 | - |
dc.relation.isPartOf | FRONTIERS IN IMMUNOLOGY | - |
dc.citation.title | FRONTIERS IN IMMUNOLOGY | - |
dc.citation.volume | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | ADOPTIVE IMMUNOTHERAPY | - |
dc.subject.keywordPlus | CANCER-IMMUNOTHERAPY | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | MEMORY | - |
dc.subject.keywordPlus | DIFFERENTIATION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | EOMESODERMIN | - |
dc.subject.keywordPlus | BET | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordAuthor | mouse embryonic fibroblast-conditioned medium | - |
dc.subject.keywordAuthor | CD8(+) T cells | - |
dc.subject.keywordAuthor | cytotoxic T lymphocytes | - |
dc.subject.keywordAuthor | long-term persistence | - |
dc.subject.keywordAuthor | adoptive T cell therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.